Effects of etelcalcetide on fibroblast growth factor 23 in patients with secondary hyperparathyroidism receiving hemodialysis

Clinical Kidney Journal

Volumn 13, Issue 1, 2019, Pages 75-84

  Wolf, Myles ^a   Block, Geoffrey A ^b   Chertow, Glenn M ^c   Cooper, Kerry ^d   Fouqueray, Bruno ^d   Moe, Sharon M ^e   Sun, Yan ^d   Tomlin, Holly ^d   Vervloet, Marc ^f   Oberbauer, Rainer ^g  

^a DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^b Denver Nephrology   (United States)

^c STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d AMGEN INC   (United States)

^e INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^g MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

calcimimetics; FGF23; hemodialysis; PTH; secondary hyperparathyroidism

Indexed keywords

CALCIUM PHOSPHATE; CINACALCET; ETELCALCETIDE; FIBROBLAST GROWTH FACTOR 23; PARATHYROID HORMONE; PLACEBO; VITAMIN D;

ADULT; ARTICLE; BONE TURNOVER; CALCIUM BLOOD LEVEL; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; FEMALE; HEMODIALYSIS; HUMAN; HYPOCALCEMIA; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PARATHYROIDECTOMY; PRIORITY JOURNAL; SECONDARY HYPERPARATHYROIDISM; TREATMENT OUTCOME; VITAMIN SUPPLEMENTATION;

EID: 85079929108     PISSN: 20488505     EISSN: 20488513     Source Type: Journal    
DOI: 10.1093/ckj/sfz034     Document Type: Article

References (44)

1. Wolf M. Update on fibroblast growth factor 23 in chronic kidney disease. Kidney Int 2012; 82: 737-747
2. Gutierrez O, Isakova T, Rhee E et al. Fibroblast growth factor-23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney disease. J Am Soc Nephrol 2005; 16: 2205-2215
3. Liu S, Tang W, Zhou J et al. Fibroblast growth factor 23 is a counter-regulatory phosphaturic hormone for vitamin D. J Am Soc Nephrol 2006; 17: 1305-1315
4. Stubbs J, Liu S, Quarles LD. Role of fibroblast growth factor 23 in phosphate homeostasis and pathogenesis of disordered mineral metabolism in chronic kidney disease. Semin Dial 2007; 20: 302-308
5. Gattineni J, Bates C, Twombley K et al. FGF23 decreases renal NaPi-2a and NaPi-2c expression and induces hypophosphatemia in vivo predominantly via FGF receptor 1. Am J Physiol Renal Physiol 2009; 297: F282-F291
6. Zisman AL, Wolf M. Recent advances in the rapidly evolving field of fibroblast growth factor 23 in chronic kidney disease. Curr Opin Nephrol Hypertens 2010; 19: 335-342
7. Gattineni J, Alphonse P, Zhang Q et al. Regulation of renal phosphate transport by FGF23 is mediated by FGFR1 and FGFR4. Am J Physiol Renal Physiol 2014; 306: F351-F358
8. Razzaque MS. Bone-kidney axis in systemic phosphate turnover. Arch Biochem Biophys 2014; 561: 154-158
9. Shigematsu T, Kazama JJ, Yamashita T, et al. Possible involvement of circulating fibroblast growth factor 23 in the development of secondary hyperparathyroidism associated with renal insufficiency. Am J Kidney Dis 2004; 44: 250-256
10. Gutierrez OM, Mannstadt M, Isakova T et al. Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N Engl J Med 2008; 359: 584-592
11. Kendrick J, Cheung AK, Kaufman JS et al. FGF-23 associates with death, cardiovascular events, and initiation of chronic dialysis. J Am Soc Nephrol 2011; 22: 1913-1922
12. Isakova T, Xie H, Yang W et al. Fibroblast growth factor 23 and risks of mortality and end-stage renal disease in patients with chronic kidney disease. JAMA 2011; 305: 2432-2439
13. Sprague SM, Wetmore JB, Gurevich K et al. Effect of cinacalcet and vitamin D analogs on fibroblast growth factor-23 during the treatment of secondary hyperparathyroidism. Clin J Am Soc Nephrol 2015; 10: 1021-1030
14. Pichler G, Haller MC, Kainz A, et al. Prognostic value of boneand vascular-derived molecular biomarkers in hemodialysis and renal transplant patients: a systematic review and meta-analysis. Nephrol Dial Transplant 2017; 32: 1566-1578
15. Ketteler M, Block GA, Evenepoel P et al. Executive summary of the 2017 KDIGO chronic kidney disease-mineral and bone disorder (CKD-MBD) guideline update: what's changed and why it matters. Kidney Int 2017; 92: 26-36
16. Cozzolino M, Ketteler M, Martin KJ et al. Paricalcitol-or cinacalcet-centred therapy affects markers of bone mineral disease in patients with secondary hyperparathyroidism receiving haemodialysis: results of the IMPACT-SHPT study. Nephrol Dial Transplant 2014; 29: 899-905
17. Hansen D, Rasmussen K, Pedersen SM et al. Changes in fibroblast growth factor 23 during treatment of secondary hyperparathyroidism with alfacalcidol or paricalcitol. Nephrol Dial Transplant 2012; 27: 2263-2269
18. Hryszko T, Brzosko S, Rydzewska-Rosolowska A et al. Cinacalcet lowers FGF-23 level together with bone metabolism in hemodialyzed patients with secondary hyperparathyroidism. Int Urol Nephrol 2012; 44: 1479-1486
19. Kim HJ, Kim H, Shin N et al. Cinacalcet lowering of serum fibroblast growth factor-23 concentration may be independent from serum Ca, P, PTH and dose of active vitamin D in peritoneal dialysis patients: a randomized controlled study. BMC Nephrol 2013; 14: 112
20. Koizumi M, Komaba H, Nakanishi S et al. Cinacalcet treatment and serum FGF23 levels in haemodialysis patients with secondary hyperparathyroidism. Nephrol Dial Transplant 2012; 27: 784-790
21. Wesseling-Perry K, Pereira RC, Sahney S et al. Calcitriol and doxercalciferol are equivalent in controlling bone turnover, suppressing parathyroid hormone, and increasing fibroblast growth factor-23 in secondary hyperparathyroidism. Kidney Int 2011; 79: 112-119
22. Wetmore JB, Liu S, Krebill R et al. Effects of cinacalcet and concurrent low-dose vitamin D on FGF23 levels in ESRD. Clin J Am Soc Nephrol 2010; 5: 110-116
23. Ketteler M, Martin KJ, Wolf M et al. Paricalcitol versus cinacalcet plus low-dose vitamin D therapy for the treatment of secondary hyperparathyroidism in patients receiving haemodialysis: results of the IMPACT SHPT study. Nephrol Dial Transplant 2012; 27: 3270-3278
24. Block GA, Bushinsky DA, Cunningham J et al. Effect of etelcalcetide vs placebo on serum parathyroid hormone in patients receiving hemodialysis with secondary hyperparathyroidism: two randomized clinical trials. JAMA 2017; 317: 146-155
25. Block GA, Bushinsky DA, Cheng S et al. Effect of etelcalcetide vs cinacalcet on serum parathyroid hormone in patients receiving hemodialysis with secondary hyperparathyroidism: a randomized clinical trial. JAMA 2017; 317: 156-164
26. Burnett-Bowie SM, Henao MP, Dere ME et al. Effects of hPTH(1-34) infusion on circulating serum phosphate, 1,25-dihydroxyvitamin D, and FGF23 levels in healthy men. J Bone Miner Res 2009; 24: 1681-1685
27. Lavi-Moshayoff V, Wasserman G, Meir T et al. PTH increases FGF23 gene expression and mediates the high-FGF23 levels of experimental kidney failure: a bone parathyroid feedback loop. Am J Physiol Renal Physiol 2010; 299: F882-F889
28. Lopez I, Rodriguez-Ortiz ME, Almaden Y, et al. Direct and indirect effects of parathyroid hormone on circulating levels of fibroblast growth factor 23 in vivo. Kidney Int 2011; 80: 475-482
29. Rhee Y, Bivi N, Farrow E et al. Parathyroid hormone receptor signaling in osteocytes increases the expression of fibroblast growth factor-23 in vitro and in vivo. Bone 2011; 49: 636-643
30. Nabeshima Y. Discovery of a-Klotho and FGF23 unveiled new insight into calcium and phosphate homeostasis. Clin Calcium 2008; 18: 923-934
31. Olauson H, Lindberg K, Amin R et al. Targeted deletion of Klotho in kidney distal tubule disrupts mineral metabolism. J Am Soc Nephrol 2012; 23: 1641-1651
32. Erben RG, Andrukhova O. FGF23-Klotho signaling axis in the kidney. Bone 2017; 100: 62-68
33. Soriano S, Ojeda R, Rodriguez Met al. The effect of phosphate binders, calcium and lanthanum carbonate on FGF23 levels in chronic kidney disease patients. Clin Nephrol 2013; 80: 17-22
34. Koiwa F, Kazama JJ, Tokumoto A et al. Sevelamer hydrochloride and calcium bicarbonate reduce serum fibroblast growth factor 23 levels in dialysis patients. Ther Apher Dial 2005; 9: 336-339
35. Lin HH, Liou HH, Wu MS et al. Long-term sevelamer treatment lowers serum fibroblast growth factor 23 accompanied with increasing serum Klotho levels in chronic haemodialysis patients. Nephrology (Carlton) 2014; 19: 672-678
36. Iguchi A, Yamamoto S, Yamazaki M, et al. Effect of ferric citrate hydrate on FGF23 and PTH levels in patients with nondialysis-dependent chronic kidney disease with normophosphatemia and iron deficiency. Clin Exp Nephrol 2018; 22: 789-796
37. Cancela AL, Oliveira RB, Graciolli FG et al. Fibroblast growth factor 23 in hemodialysis patients: effects of phosphate binder, calcitriol and calcium concentration in the dialysate. Nephron Clin Pract 2011; 117: c74-c82
38. Rodriguez-Ortiz ME, Lopez I, Munoz-Castaneda JR et al. Calcium deficiency reduces circulating levels of FGF23. J Am Soc Nephrol 2012; 23: 1190-1197
39. Quinn SJ, Thomsen AR, Pang JL, et al. Interactions between calcium and phosphorus in the regulation of the production of fibroblast growth factor 23 in vivo. Am J Physiol Endocrinol Metab 2013; 304: E310-E320
40. Wesseling-Perry K, Harkins GC, Wang et al. The calcemic response to continuous parathyroid hormone (PTH)(1-34) infusion in end-stage kidney disease varies according to bone turnover: a potential role for PTH(7-84). J Clin Endocrinol Metab 2010; 95: 2772-2780
41. Meir T, Durlacher K, Pan Z et al. Parathyroid hormone activates the orphan nuclear receptor Nurr1 to induce FGF23 transcription. Kidney Int 2014; 86: 1106-1115
42. Sato T, Tominaga Y, Ueki T et al. Total parathyroidectomy reduces elevated circulating fibroblast growth factor 23 in advanced secondary hyperparathyroidism. Am J Kidney Dis 2004; 44: 481-487
43. Liao SC, Moi SH, Chou FF et al. Changes in serum concentrations of fibroblast growth factor 23 and soluble klotho in hemodialysis patients after total parathyroidectomy. Biomed Res Int 2016; 2016: 6453803
44. Tocados JMD, Ortiz MER, Almaden Y et al. In uremic rats, the calcimimetic maintains bone turnover in a parathyroid hormone-independentmanner. Annual Congress of the American Society of Nephrology 2016